11,000 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Acquired by Triglav Skladi D.O.O.

Triglav Skladi D.O.O. purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 11,000 shares of the company’s stock, valued at approximately $1,502,000.

A number of other institutional investors and hedge funds have also modified their holdings of NBIX. Dodge & Cox grew its holdings in shares of Neurocrine Biosciences by 134.2% in the 4th quarter. Dodge & Cox now owns 3,016,425 shares of the company’s stock worth $411,742,000 after acquiring an additional 1,728,605 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Neurocrine Biosciences in the 4th quarter worth approximately $115,193,000. Wellington Management Group LLP grew its holdings in shares of Neurocrine Biosciences by 102.9% in the 4th quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company’s stock worth $198,939,000 after acquiring an additional 739,199 shares during the period. Thrivent Financial for Lutherans grew its holdings in Neurocrine Biosciences by 2,759.4% during the 4th quarter. Thrivent Financial for Lutherans now owns 737,772 shares of the company’s stock valued at $100,705,000 after buying an additional 711,970 shares during the last quarter. Finally, Orbimed Advisors LLC grew its holdings in Neurocrine Biosciences by 210.4% during the 4th quarter. Orbimed Advisors LLC now owns 938,120 shares of the company’s stock valued at $128,053,000 after buying an additional 635,900 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on NBIX shares. Needham & Company LLC raised their price target on Neurocrine Biosciences from $138.00 to $139.00 and gave the stock a “buy” rating in a research report on Tuesday, May 6th. JPMorgan Chase & Co. raised their price target on Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 26th. Royal Bank of Canada raised their price target on Neurocrine Biosciences from $137.00 to $145.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 6th. Bank of America dropped their price target on Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, Guggenheim raised their price target on Neurocrine Biosciences from $155.00 to $165.00 and gave the stock a “buy” rating in a research report on Tuesday, May 6th. Three investment analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $162.00.

Insider Activity at Neurocrine Biosciences

In related news, Director William H. Rastetter sold 30,000 shares of Neurocrine Biosciences stock in a transaction on Monday, May 5th. The stock was sold at an average price of $110.20, for a total value of $3,306,000.00. Following the transaction, the director now owns 37,491 shares in the company, valued at approximately $4,131,508.20. This trade represents a 44.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.80% of the stock is owned by insiders.

Neurocrine Biosciences Trading Up 0.6%

Shares of Neurocrine Biosciences stock opened at $121.02 on Monday. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $157.98. The stock has a market capitalization of $11.98 billion, a P/E ratio of 36.78, a PEG ratio of 0.77 and a beta of 0.26. The business’s fifty day moving average price is $107.02 and its 200 day moving average price is $121.92.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. The firm had revenue of $572.60 million during the quarter, compared to analyst estimates of $587.06 million. During the same quarter in the previous year, the business posted $1.20 EPS. Neurocrine Biosciences’s revenue was up 11.1% compared to the same quarter last year. As a group, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences declared that its Board of Directors has approved a share buyback program on Friday, February 21st that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 4.2% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.